CRISPR Therapeutics nominates Dr. Maria Fardis for election to its Board of Directors

– SWITZERLAND, Zug / USA, MA –  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company today announced the nomination of Dr. Maria Fardis (Ph.D.,) for her election to its Board of Directors at the upcoming AGM later this year.

“We are very pleased to invite Maria to join our Board of Directors. Her extensive leadership in scaling companies and bringing novel therapies to patients will be an invaluable asset to CRISPR Therapeutics as we continue to advance our pipeline and platform to develop transformative medicines for patients suffering from serious diseases,” said CEO, Dr. Samarth Kulkarni.

About Dr. Maria Fardis

Maria Fardis, Ph.D., MBA, has been a venture partner at Frazier Life Sciences since 2021. Dr. Fardis previously served as President and CEO of Iovance Biotherapeutics, Inc. (Nasdaq: IOVA), a biopharmaceutical company, and as a member of its Board of Directors from June 2016 through June 2021. She previously served as COO of Acerta Pharma B.V., a biopharmaceutical company, from 2015 to 2016. From 2011 to 2014, she was at Pharmacyclics, Inc. and served as Chief of Oncology Operations and Alliances. Before joining Pharmacyclics, from 2001 to 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management at Gilead Sciences, Inc.

Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley, and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. She holds an M.B.A. from Golden Gate University.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.

For more information: http://www.crisprtx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team